MCID: PNC025
MIFTS: 57

Panic Disorder

Categories: Mental diseases, Respiratory diseases

Aliases & Classifications for Panic Disorder

MalaCards integrated aliases for Panic Disorder:

Name: Panic Disorder 12 77 38 56 44 45 15 17 74
Panic Anxiety Syndrome 12
Panic Disorder 1 74
Panic 56

Classifications:



External Ids:

Disease Ontology 12 DOID:594
KEGG 38 H01664
MeSH 45 D016584
NCIt 51 C34890
ICD10 34 F41.0

Summaries for Panic Disorder

MedlinePlus : 44 Panic disorder is a type of anxiety disorder. It causes panic attacks, which are sudden feelings of terror when there is no real danger. You may feel as if you are losing control. You may also have physical symptoms, such as Fast heartbeat Chest or stomach pain Breathing difficulty Weakness or dizziness Sweating Feeling hot or a cold chill Tingly or numb hands Panic attacks can happen anytime, anywhere, and without warning. You may live in fear of another attack and may avoid places where you have had an attack. For some people, fear takes over their lives and they cannot leave their homes. Panic disorder is more common in women than men. It usually starts when people are young adults. Sometimes it starts when a person is under a lot of stress. Most people get better with treatment. Therapy can show you how to recognize and change your thinking patterns before they lead to panic. Medicines can also help. NIH: National Institute of Mental Health

MalaCards based summary : Panic Disorder, also known as panic anxiety syndrome, is related to panic disorder 1 and anxiety. An important gene associated with Panic Disorder is MIR22 (MicroRNA 22), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Paroxetine Pathway, Pharmacokinetics. The drugs Paroxetine and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress.

Wikipedia : 77 Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic... more...

Related Diseases for Panic Disorder

Diseases in the Panic Disorder family:

Panic Disorder 1 Panic Disorder 2
Panic Disorder 3

Diseases related to Panic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 panic disorder 1 34.9 COMT PAND1
2 anxiety 32.2 CCKBR COMT CRH HTR1A HTR2A HTR3A
3 phobic disorder 32.1 COMT HTR1A MAOA PTK7 SLC6A4
4 agoraphobia 32.0 CCKBR HTR1A MAOA PTK7 SLC6A2 SLC6A4
5 depression 31.7 CRH HTR1A HTR2A MAOA SLC6A4 TPH2
6 social phobia 31.5 CCK HTR1A HTR3A MAOA SLC6A4
7 personality disorder 31.3 COMT HTR1A HTR2A MAOA SLC6A4
8 alexithymia 31.3 COMT HTR1A SLC6A4
9 generalized anxiety disorder 31.1 COMT HTR1A HTR2A HTR3A MAOA SLC6A2
10 phobia, specific 31.0 COMT MAOA
11 obsessive-compulsive disorder 30.9 COMT CRH HTR1A HTR2A HTR3A MAOA
12 irritable bowel syndrome 30.8 CCK CRH HTR3A SLC6A4
13 dysthymic disorder 30.8 HTR2A MAOA SLC6A4
14 major depressive disorder 30.8 COMT CRH HTR1A HTR2A HTR3A MAOA
15 endogenous depression 30.7 CRH HTR1A HTR2A MAOA SLC6A4
16 substance abuse 30.7 COMT MAOA SLC6A4
17 post-traumatic stress disorder 30.7 COMT CRH HTR2A MAOA SLC6A4
18 eating disorder 30.6 CCK COMT CRH SLC6A4
19 bipolar disorder 30.6 COMT DAOA-AS1 HTR1A HTR2A SLC6A4
20 mental depression 30.4 COMT CRH HTR1A HTR2A MAOA SLC6A2
21 atypical depressive disorder 30.3 CRH HTR2A MAOA SLC6A4
22 conduct disorder 30.3 COMT MAOA SLC6A4
23 alcohol dependence 30.3 CCK COMT HTR1A HTR2A HTR3A MAOA
24 bulimia nervosa 30.3 CCK COMT HTR2A HTR3A SLC6A4
25 disease of mental health 30.2 CCK COMT CRH HTR1A HTR2A MAOA
26 dyspepsia 30.2 CCK CCKAR HTR1A HTR3A SLC6A4
27 premature ejaculation 30.2 HTR1A HTR3A SLC6A4
28 borderline personality disorder 30.2 COMT HTR1A HTR2A MAOA SLC6A4 TPH2
29 tobacco addiction 30.2 COMT HTR2A MAOA SLC6A4
30 mood disorder 30.2 COMT CRH HTR1A HTR2A MAOA SLC6A2
31 bipolar i disorder 30.2 COMT HTR1A HTR2A SLC6A4
32 tardive dyskinesia 30.2 COMT HTR2A
33 avoidant personality disorder 30.2 MAOA SLC6A4
34 cocaine abuse 30.1 HTR3A SLC6A2 SLC6A4
35 fibromyalgia 30.1 COMT CRH HTR2A HTR3A SLC6A4 TSPO
36 schizoaffective disorder 30.1 COMT HTR2A SLC6A4
37 anorexia nervosa 30.1 CCK COMT CRH HTR2A SLC6A4
38 attention deficit-hyperactivity disorder 30.0 COMT HTR1A HTR2A MAOA SLC6A2 SLC6A4
39 sudden infant death syndrome 29.7 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH2
40 schizophrenia 29.7 CCK CCKAR COMT DAOA-AS1 HTR1A HTR2A
41 panic disorder 3 12.5
42 panic disorder 2 12.3
43 dystonia 11, myoclonic 11.1
44 cancerophobia 11.1
45 autoimmune encephalitis 11.1
46 misophonia 11.1
47 orthostatic intolerance 10.5
48 kleptomania 10.4 HTR1A MAOA SLC6A4
49 schizoid personality disorder 10.4 HTR1A HTR2A
50 pathological gambling 10.4 HTR2A MAOA SLC6A4

Graphical network of the top 20 diseases related to Panic Disorder:



Diseases related to Panic Disorder

Symptoms & Phenotypes for Panic Disorder

GenomeRNAi Phenotypes related to Panic Disorder according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Panic Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 CCKAR CCKBR COMT CRH HTR1A HTR2A
2 cardiovascular system MP:0005385 9.97 CCKBR COMT HTR1A MAOA PTK7 SLC6A2
3 homeostasis/metabolism MP:0005376 9.93 CCK CCKAR CCKBR COMT CRH HTR1A
4 endocrine/exocrine gland MP:0005379 9.91 CCK CCKAR CCKBR COMT CRH HTR2A
5 nervous system MP:0003631 9.73 CCK CCKAR CCKBR COMT CRH HTR1A
6 renal/urinary system MP:0005367 9.17 CCK CCKAR CCKBR COMT CRH HTR3A

Drugs & Therapeutics for Panic Disorder

Drugs for Panic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
2
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
4
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
5
Citalopram Approved Phase 4,Phase 1,Not Applicable 59729-33-8 2771
6
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1 79617-96-2 68617
7
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
8
Clonazepam Approved, Illicit Phase 4,Phase 2,Phase 3 1622-61-3 2802
9
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 28981-97-7 2118
10
Clozapine Approved Phase 4 5786-21-0 2818
11
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106266-06-2 5073
12
Ziprasidone Approved Phase 4 146939-27-7 60854
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
15
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
16
Suvorexant Approved, Investigational Phase 4 1030377-33-3
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
19
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
20
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
21
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
22 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Anticonvulsants Phase 4,Phase 2,Phase 3
33 Quetiapine Fumarate Phase 4,Not Applicable 111974-72-2
34 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Antimanic Agents Phase 4
36 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 1,Not Applicable,Early Phase 1
40 Duloxetine Hydrochloride Phase 4
41 Analgesics Phase 4,Not Applicable
42 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
43 Antiparkinson Agents Phase 4,Phase 1,Not Applicable
44 Cholinergic Antagonists Phase 4,Phase 1,Not Applicable
45 Muscarinic Antagonists Phase 4,Phase 1,Not Applicable
46 Autonomic Agents Phase 4,Phase 1,Not Applicable,Early Phase 1
47 Parasympatholytics Phase 4,Phase 1,Not Applicable
48 Cholinergic Agents Phase 4,Phase 1,Not Applicable,Early Phase 1
49 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2
50 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
4 A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients Completed NCT00619892 Phase 4 quetiapine XR;placebo
5 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
6 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
7 Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
8 Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder Completed NCT00767754 Phase 4 Paxil CR
9 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
10 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
11 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
12 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment Completed NCT00803400 Phase 4 Alprazolam;Alprazolam + Aerobic exercise
13 Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression Completed NCT00031317 Phase 4 Paroxetine;Clozapine
14 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
15 A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients Completed NCT00198094 Phase 4 Sertraline and Alprazolam XR
16 A Study of Risperidone Monotherapy in Bipolar Anxiety Completed NCT00167479 Phase 4 risperidone (Risperdal)
17 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Completed NCT01172652 Phase 4 Ziprasidone;Placebo
18 Aripiprazole for the Treatment of Refractory Anxiety Completed NCT00438386 Phase 4 Aripiprazole
19 The Effects of Treatment With Sertraline for Noncardiac Chest Pain Completed NCT01114100 Phase 4 sertraline;placebo
20 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
21 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
22 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
23 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
24 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Non Cardiac Chest Pain and Benign Palpitations Completed NCT00623454 Phase 4
26 Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder Completed NCT00391430 Phase 4 Sertraline
27 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
28 Guanfacine Extended Release and Mindfulness Skills Therapy Recruiting NCT03258476 Phase 4 Guanfacine Extended Release;Placebo
29 The Role of Orexin in Human Panic Disorder Active, not recruiting NCT02593682 Phase 4 suvorexant;placebo
30 Ketamine Infusion for Adolescent Depression and Anxiety Active, not recruiting NCT02579928 Phase 4 Ketamine;Midazolam
31 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
32 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
33 Clinical Utility of Pharmacogenomics of Psychotropic Medications Not yet recruiting NCT03907124 Phase 4 Genetically-guided treatment with FDA-approved psychotropic drugs;Treatment as usual (TAU)
34 A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder Terminated NCT00635531 Phase 4 alprazolam XR
35 A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder Terminated NCT00635076 Phase 4 alprazolam XR
36 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
37 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
38 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
39 Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder Completed NCT00195598 Phase 3 VENLAFAXINE;Paroxetine
40 Psychodynamic Therapy for Treating Panic Disorder Completed NCT00128388 Phase 2, Phase 3
41 Therapies for Treatment-Resistant Panic Disorder Symptoms Completed NCT00118417 Phase 2, Phase 3 Clonazepam;Sertraline
42 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
43 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
44 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
45 Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks Completed NCT00279617 Phase 3 levetiracetam
46 Study Evaluating Venlafaxine ER in Patients With Panic Disorder Completed NCT00044772 Phase 3 Venlafaxine ER
47 Study Evaluating Venlafaxine ER in Adults With Panic Disorder Completed NCT00038896 Phase 3 Venlafaxine ER
48 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
49 Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders Completed NCT00102427 Phase 2, Phase 3
50 Telephone-Based Care Management Program for Individuals With Anxiety Disorders Completed NCT00158327 Phase 3

Search NIH Clinical Center for Panic Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: panic disorder

Genetic Tests for Panic Disorder

Anatomical Context for Panic Disorder

MalaCards organs/tissues related to Panic Disorder:

42
Heart, Brain, Testes, Cortex, Amygdala, Thyroid, Colon

Publications for Panic Disorder

Articles related to Panic Disorder:

(show top 50) (show all 3248)
# Title Authors Year
1
The impact of depressive comorbidity on neural plasticity following cognitive-behavioral therapy in panic disorder with agoraphobia. ( 30428445 )
2019
2
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. ( 30718541 )
2019
3
Heart rate variability in patients with agoraphobia with or without panic disorder remains stable during CBT but increases following in-vivo exposure. ( 30875662 )
2019
4
Allergic rhinitis increases the risk of incident panic disorder among young individuals: A nationwide population-based cohort study in Taiwan. ( 30981057 )
2019
5
Treatment of anxiety and mood comorbidities in cognitive-behavioral and psychodynamic therapies for panic disorder. ( 31015099 )
2019
6
Will the RANZCP clinical practice guidelines for the treatment of anxiety disorders assist in making adequate treatment decisions for panic disorder? ( 30518224 )
2019
7
Commentary on RANZCP clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. ( 30511582 )
2019
8
Clinical and Neurofunctional Substrates of Cognitive Behavioral Therapy on Secondary Social Anxiety Disorder in Primary Panic Disorder: A Longitudinal fMRI Study. ( 30368504 )
2019
9
The BDNF Val66Met gene polymorphism is associated with increased alexithymic and anticipatory anxiety in patients with panic disorder. ( 30269521 )
2019
10
Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. ( 30583140 )
2019
11
The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. ( 30460734 )
2019
12
Associations of plasma testosterone with clinical manifestations in acute panic disorder. ( 30471570 )
2019
13
Characterizing the nature of emotional-associative learning deficits in panic disorder: An fMRI study on fear conditioning, extinction training and recall. ( 30497840 )
2019
14
Mediators of Change in Capnometry Guided Respiratory Intervention for Panic Disorder. ( 30539503 )
2019
15
Psychometric analysis of the Swedish panic disorder severity scale and its self-report version. ( 30636466 )
2019
16
Panic Disorder: Current Research and Management Approaches. ( 30696237 )
2019
17
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. ( 30696238 )
2019
18
The Prevalence of patients with panic attacks (PAs) and panic disorder (PD) visiting Emergency Departments of the Verona Hospital. ( 30714607 )
2019
19
High-Intensity Interval Training in Panic Disorder Patients: A Pilot Study. ( 30724830 )
2019
20
Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder. ( 30742590 )
2019
21
Brain activation during disorder-related script-driven imagery in panic disorder: a pilot study. ( 30787382 )
2019
22
Comparison of Cortisol Stress Response in Patients with Panic Disorder, Cannabis-Induced Panic Disorder, and Healthy Controls. ( 30879013 )
2019
23
Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient. ( 30905115 )
2019
24
Physical activity is indirectly associated with pain in college women through associations with somatization and panic disorder symptoms: a cross-sectional study. ( 30905543 )
2019
25
Benzodiazepines versus placebo for panic disorder in adults. ( 30921478 )
2019
26
Vestibular function in panic disorder patients: a vestibular-evoked myogenic potentials and video head impulse test study. ( 30923888 )
2019
27
Importance of knowledge in the behavioural treatment of panic disorder. ( 30935431 )
2019
28
Reduced Sensitivity to Non-Fear-Related Stimulus Changes in Panic Disorder. ( 30947222 )
2019
29
Elevated peripheral kynurenine/tryptophan ratio predicts poor short-term auditory memory in panic disorder patients. ( 30959226 )
2019
30
Meta-Analysis of Neuropsychological Studies in Panic Disorder Patients: Evidence of Impaired Performance during the Emotional Stroop Task. ( 30970364 )
2019
31
Can sleep disturbance be a cue of mood spectrum comorbidity? A preliminary study in panic disorder. ( 30971322 )
2019
32
A panel of miRNAs is involved in the effect of sertraline on panic disorder, as implicated by a microarray-based analysis. ( 30974330 )
2019
33
Diagnostic Utility of Sodium Lactate Infusion and CO2-35% Inhalation for Panic Disorder. ( 30982042 )
2019
34
Panic Disorder in Primary Care. ( 30995952 )
2019
35
The prevalence of panic disorder and its related factor in hospitalized patients with chest pain and normal angiography. ( 31008128 )
2019
36
Abnormal frontal generator during auditory sensory gating in panic disorder: An MEG study. ( 31014913 )
2019
37
Emotion Regulation Strategies in Cognitive Behavioral Therapy for Panic Disorder. ( 31030881 )
2019
38
The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science. ( 31061640 )
2019
39
Symptom trajectories in patients with panic disorder in a primary care intervention: Results from a randomized controlled trial (PARADISE). ( 31073189 )
2019
40
Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients. ( 29113874 )
2019
41
The neural markers of MRI to differentiate depression and panic disorder. ( 29705713 )
2019
42
A Novel Bio-Psychosocial-Behavioral Treatment Model of Panic Disorder. ( 30301303 )
2019
43
Biological and Clinical Markers in Panic Disorder. ( 30184613 )
2019
44
Fear Network Model in Panic Disorder: The Past and the Future. ( 30176707 )
2019
45
Internet-Delivered Psychological Treatment Options for Panic Disorder: A Review on Their Efficacy and Acceptability. ( 30122031 )
2019
46
N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents. ( 30078111 )
2019
47
Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. ( 29391399 )
2018
48
Pretreatment Cardiac Vagal Tone Predicts Dropout from and Residual Symptoms after Exposure Therapy in Patients with Panic Disorder and Agoraphobia. ( 29533952 )
2018
49
Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. ( 29539585 )
2018
50
The relationship between impulsivity and panic disorder-agoraphobia: The role of affective temperament. ( 29649673 )
2018

Variations for Panic Disorder

Expression for Panic Disorder

Search GEO for disease gene expression data for Panic Disorder.

Pathways for Panic Disorder

Pathways related to Panic Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH2
2
Show member pathways
11.67 COMT SLC6A2 SLC6A4
3 11.49 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH2
4
Show member pathways
11.19 MAOA SLC6A2 SLC6A4 TPH2
5
Show member pathways
10.93 COMT MAOA SLC6A4
6
Show member pathways
10.82 COMT MAOA
7
Show member pathways
10.6 COMT MAOA
8 10.58 COMT MAOA
9 10.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH2
10 10.52 CCK CCKBR

GO Terms for Panic Disorder

Cellular components related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 CCKAR HTR1A HTR2A HTR3A PTK7 SLC6A2
2 axon GO:0030424 9.56 CCK COMT HTR2A HTR3A
3 integral component of presynaptic membrane GO:0099056 9.13 HTR2A HTR3A SLC6A4
4 integral component of postsynaptic membrane GO:0099055 8.8 HTR2A HTR3A SLC6A4

Biological processes related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 CCK CCKBR CRH HTR1A HTR2A
2 chemical synaptic transmission GO:0007268 9.77 CRH HTR1A HTR2A HTR3A SLC6A2
3 memory GO:0007613 9.74 CCK HTR2A SLC6A4
4 response to estrogen GO:0043627 9.67 COMT CRH TPH2
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.63 CCKAR CCKBR HTR2A
6 response to drug GO:0042493 9.63 COMT CRH HTR2A SLC6A2 SLC6A4 TSPO
7 adrenal gland development GO:0030325 9.6 CRH TSPO
8 vasoconstriction GO:0042310 9.59 HTR1A SLC6A4
9 catecholamine metabolic process GO:0006584 9.56 COMT MAOA
10 neurotransmitter catabolic process GO:0042135 9.55 COMT MAOA
11 behavior GO:0007610 9.54 HTR1A HTR2A
12 monoamine transport GO:0015844 9.52 SLC6A2 SLC6A4
13 positive regulation of mitochondrial depolarization GO:0051901 9.51 CCK TSPO
14 dopamine catabolic process GO:0042420 9.48 COMT MAOA
15 positive regulation of behavioral fear response GO:2000987 9.43 CCK CRH
16 regulation of hormone secretion GO:0046883 9.4 CCKAR HTR1A
17 cholecystokinin signaling pathway GO:0038188 9.32 CCKAR CCKBR
18 regulation of serotonin secretion GO:0014062 9.26 CRH HTR1A
19 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR3A
20 response to pain GO:0048265 8.92 COMT CRH SLC6A2 TSPO
21 signal transduction GO:0007165 10.18 CCK CCKAR CCKBR CRH HTR1A HTR2A

Molecular functions related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter:sodium symporter activity GO:0005328 9.26 SLC6A2 SLC6A4
2 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A2 SLC6A4
3 cholecystokinin receptor activity GO:0004951 8.96 CCKAR CCKBR
4 serotonin binding GO:0051378 8.92 HTR1A HTR2A HTR3A SLC6A4

Sources for Panic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....